Greenwich LifeSciences, Inc.

NasdaqCM:GLSI Stock Report

Market Cap: US$198.7m

Greenwich LifeSciences Future Growth

Future criteria checks 0/6

Greenwich LifeSciences is forecast to grow earnings at 12.3% per annum. EPS is expected to grow by 18.1% per annum.

Key information

12.3%

Earnings growth rate

18.10%

EPS growth rate

Biotechs earnings growth24.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated21 Jul 2026

Recent future growth updates

Recent updates

Seeking Alpha • Jul 16

Greenwich LifeSciences The Overlooked Need

Summary Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-positive breast cancer, currently in Phase 3 trials. GLSI-100 demonstrated a 70-80% reduction in cancer recurrence in Phase 2b, outperforming approved therapies, with no serious adverse events reported. GLSI trades at a ~$279M market cap, below recent M&A comps, despite advanced clinical progress and a large addressable market in HER2/neu-positive breast cancer. Risks include binary dependency on GLSI-100 Phase 3 success and near-term need for additional capital, given limited cash reserves. Read the full article on Seeking Alpha
New Narrative • Mar 18

Greenwich LifeSciences will eye a valued future at $460 a share, with GP2 leading the way.

SUMMARY:
Analysis Article • Aug 22

We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 26

Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge

Summary Greenwich LifeSciences, Inc. is a late-stage biotech company focusing on developing an immunotherapy treatment for breast cancer. Their pipeline includes one drug, GLSI-100, currently in a phase 3 trial targeting breast cancer recurrence after surgery. Financially, Greenwich LifeSciences has limited resources with a cash runway of approximately 2 quarters, making it a high-risk investment. Read the full article on Seeking Alpha
Analysis Article • Jan 12

Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 29

We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 06

Greenwich LifeSciences: Persevering CEO And Interesting Data

Summary Greenwich LifeSciences, Inc. is a one-man, one-asset shop. The asset, GP2, has produced excellent breast cancer data. Greenwich LifeSciences' CEO, Snehal Patel, runs this company almost all by himself. Greenwich LifeSciences, Inc. (GLSI) is a developer of cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. A 2-year IPO with a 2 decades history, GLSI had been lagging over an FDA clinical hold that was placed on its Phase III clinical trial, FLAMINGO-01, citing manufacturing and pharmacy process issues. The stock seems to have stabilized after that, however, at $8 today, it is still nowhere near its 52-week high of $48. GLSI's lead product candidate is GLSI-100, which is a combination of GP2 and GM-CSF. GP2 is a "9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers." This is developed at GLSI. To this is added a GM-CSF, or a recombinant human granulocyte macrophage colony-stimulating factor (sargramostim, Leukine®), a well-known, previously approved molecule. The company is currently running a phase 3 trial led by Baylor and a ​"consortium of prominent cancer centers." A phase 2b trial led by MD Anderson produced solid data. Data was: 0% recurrences over median 5 years follow-up, if fully immunized, versus 11% placebo recurrence rate in 96 patients (p = 0.0338), peak immunity after 6 months, minimal to no side effects, no SAEs attributable to GP2 These patients were on a previous treatment with Herceptin or Kadcyla. The data here not only demonstrates GP2's excellent profile, it also shows that the two other legacy treatments are also highly effective in this population. The opportunity, therefore, lies in those 50% of recurring disease patients who do not respond to these standards of care. As the company says: Following breast cancer surgery, HER2/neu 3+ patients receive Herceptin in the first year and then hope that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years. Herceptin reduces recurrence rates from 25% to 12%. GP2 & GM-CSF starting in Year 2 act synergistically with Herceptin to prevent cancer recurrences, if fully immunized, reducing recurrence rates from 11% to 0% at median 5 years follow-up (p = 0.0338), with minimal to no side effects & no SAEs. This synergistic treatment effect could save 1500 to 2000 patients per year from the 17000 patients that could be treated under GLSI-100's initial indication alone.
Seeking Alpha • Jul 11

Greenwich LifeSciences halts stock buyback program

Greenwich LifeSciences (NASDAQ:GLSI) said Monday it suspended its share repurchase program. GLSI repurchased ~520K shares for ~$7.5M under the program, which had been resumed in May. The firm had ~12.8M shares outstanding following the buybacks.
Seeking Alpha • May 19

Greenwich LifeSciences: A First Look

Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pending Phase 3 study launch for its only asset in the treatment of breast cancer that was originally expected to initiate in 2020 is primarily to blame. With 100% disease free survival ("DFS") in a Phase 2b study that concluded in 2018, the recent insider buying merited closer examination. A full investment analysis follows in the paragraphs below.
Seeking Alpha • Apr 21

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Greenwich LifeSciences is a stock relatively new to the market and lesser-known, as it became public in September of 2020. Not long after, the stock skyrocketed over 1000% on early data that the company's GP2 treatment reduced breast cancer recurrences to zero. While this is still a developing story, the company has a Phase III trial dead ahead, which could usher in a new wave of investors. Greenwich LifeSciences stock has pulled back almost 60% since last April, which may present buying opportunity for investors with a long-term mindset. Insiders have been buying, and with the extension of the lockup period and announcement of a share repurchase program, management seems to be telegraphing big things ahead.
Analysis Article • Feb 01

Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Sep 30

We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Earnings and Revenue Growth Forecasts

NasdaqCM:GLSI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-18N/AN/A1
12/31/2026N/A-21N/AN/A2
3/31/2026N/A-22-13-13N/A
12/31/2025N/A-19-10-10N/A
9/30/2025N/A-21-9-9N/A
6/30/2025N/A-19-9-9N/A
3/31/2025N/A-18-7-7N/A
12/31/2024N/A-17-7-7N/A
9/30/2024N/A-10-8-8N/A
6/30/2024N/A-10-7-7N/A
3/31/2024N/A-9-7-7N/A
12/31/2023N/A-9-6-6N/A
9/30/2023N/A-9-6-6N/A
6/30/2023N/A-9-6-6N/A
3/31/2023N/A-8-6-6N/A
12/31/2022N/A-8-6-6N/A
9/30/2022N/A-7-6-6N/A
6/30/2022N/A-6-6-6N/A
3/31/2022N/A-6-6-6N/A
12/31/2021N/A-5-4-4N/A
9/30/2021N/A-3-3-3N/A
6/30/2021N/A-3-2-2N/A
3/31/2021N/A-2-2-2N/A
12/31/2020N/A-2-1-1N/A
9/30/2020N/A-100N/A
6/30/2020N/A-100N/A
3/31/2020N/A-400N/A
12/31/2019N/A-3N/A0N/A
9/30/2019N/A-5N/A0N/A
12/31/2018N/A-2N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLSI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GLSI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GLSI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if GLSI's revenue is forecast to grow faster than the US market.

High Growth Revenue: GLSI is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GLSI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/04 09:44
End of Day Share Price 2026/08/04 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Greenwich LifeSciences, Inc. is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerNOBLE Capital Markets, Inc.